B Cell Lymphoma
Conference Coverage
R2 appears active in high-risk FL and MZL
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
Conference Coverage
Inhibitor produces high response rate in relapsed/refractory FL
CHICAGO – The PI3K-delta inhibitor ME-401, given with or without rituximab, produced an overall response rate of 80% in a phase 1b trial of...
News
FDA approves Polivy for DLBCL
The FDA approval is based on results of an open-label, multicenter clinical trial of 80 patients with DLBCL who had undergone at least one prior...
Conference Coverage
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCL
CHICAGO – There was “oohing and aahing” over results showing high response and survival rates for combined rituximab, lenalidomide, and ibrutinib...
Conference Coverage
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy
CHICAGO – The immediately practice changing study offers a time-limited frontline option, one expert reported.
From the Journals
Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLL
The combination of venetoclax and ibrutinib outperformed previous reports of either of the two agents alone.
News
FDA approves lenalidomide/rituximab for previously treated FL, MZL
The approval is based on results from the phase 3 AUGMENT trial, which compared the combination treatment with placebo in previously treated...
From the Journals
Genetic analysis identifies prognostic markers in CLL
A single 11q22 deletion, lacking an ATM mutation on the other allele, had the shortest progression-free survival among patients with CLL who were...
From the Journals
CD23 expression linked to improved survival in MCL
Researchers found that mantle cell lymphoma cases that were CD23 positive had a higher frequency of leukemic nonnodal presentation and CD200...
From the Journals
Trial follow-up spotlights survival gains in follicular lymphoma
The 13-year update to the GITMO-IIL trial showed the important role of complete remission in prolonged survival. This is the longest follow-up...
News
FDA approves venetoclax/obinutuzumab combo for CLL
Venetoclax/obinutuzumab was compared with venetoclax/chlorambucil in the CLL14 study and showed superior progression-free survival in previously...